Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.

Autor: Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Qiao W; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Jun; Vol. 204 (6), pp. 2259-2263. Date of Electronic Publication: 2024 Apr 11.
DOI: 10.1111/bjh.19446
Abstrakt: Targeted therapy development for acute myeloid leukaemia (AML) requires an understanding of specific expression profiles. We collected flow cytometry data on 901 AML patients and recorded aberrant CD7 expression on leukaemic blasts. 263 (29.2%) had blasts positive for CD7. CD7+ AML was more likely to be adverse risk (64.6% vs. 55.6%, p = 0.0074) and less likely to be favourable risk (15.2% vs. 24.1%, p = 0.0074) by European LeukemiaNet 2022 criteria. Overall survival was inferior (11.9 [95% CI, 9.7-15.9] vs. 19.0 months [95% CI, 16.1-23.0], p = 0.0174). At relapse, 30.4% lost and 19.0% gained CD7, suggesting moderate instability over time.
(© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: